Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Human CPT1A Antibodies:
anti-Mouse (Murine) CPT1A Antibodies:
anti-Rat (Rattus) CPT1A Antibodies:
Go to our pre-filtered search.
Human Polyclonal CPT1A Primary Antibody for IHC (p), IHC - ABIN251677
Rayner, Esau, Hussain, McDaniel, Marshall, van Gils, Ray, Sheedy, Goedeke, Liu, Khatsenko, Kaimal, Lees, Fernandez-Hernando, Fisher, Temel, Moore: Inhibition of miR-33a/b in non-human primates raises plasma HDL and lowers VLDL triglycerides. in Nature 2011
Show all 5 Pubmed References
Cow (Bovine) Polyclonal CPT1A Primary Antibody for IHC, WB - ABIN2782010
Roomets, Kivelä, Tyni: Carnitine palmitoyltransferase I and Acyl-CoA dehydrogenase 9 in retina: insights of retinopathy in mitochondrial trifunctional protein defects. in Investigative ophthalmology & visual science 2008
Show all 4 Pubmed References
Human Polyclonal CPT1A Primary Antibody for IF (p), IHC (p) - ABIN677018
Fan, Wang, Ge, Wang, Li, Kong: Betaine supplementation protects against high-fructose-induced renal injury in rats. in The Journal of nutritional biochemistry 2014
Show all 2 Pubmed References
Mouse (Murine) Polyclonal CPT1A Primary Antibody for ELISA - ABIN451728
Mazzarelli, Pucci, Bonanno, Sesti, Calvani, Spagnoli: Carnitine palmitoyltransferase I in human carcinomas: a novel role in histone deacetylation? in Cancer biology & therapy 2008
The recent findings and the current understanding of fatty acid oxidation and CPT1A in cancer have been summarized thus providing theoretical basis for this enzyme as an emerging potential molecular target in cancer therapeutic intervention. (Review)
Methylation of a CpG site in CPT1A is associated with circulating adiponectin (show ADIPOQ Antibodies) levels, likely in an obesity-dependent manner, in three population-based adult cohorts of European descent.
Furthermore, given the already low abundance of Cpt1b (show CPT1B Antibodies) in white adipose tissue, it is unlikely that decreases in its expression can quantitatively decrease whole body energy expenditure enough to contribute to an obese phenotype.
Data show that in the absence of indoleamine 2,3-dioxygenase (IDO (show IDO1 Antibodies)) inhibition, fatty acid oxidation increased along with increased activity of carnitine palmitoyltransferase I (CPT1).
our results proved CPT1A as a potential prognosticator and therapeutic target for AML (show RUNX1 Antibodies).
High CPT1A expression is associated with ovarian cancer.
Methylation at 2 CpG sites in CPT1A on chromosome 11 was significantly associated with MetS (show ETV3 Antibodies). Significant associations were replicated in both European and African ancestry participants.
CPT1 is active on the outer surface of mitochondria and serves as a regulatory site for fatty acid oxidation due to its sensitivity for malonyl-CoA. CPT1a is the hepatic isoform.
the structure of the regulatory domain of CPT1C (show CPT1C Antibodies) was determined (residues Met1 (show GZMM Antibodies)-Phe50) by NMR spectroscopy.
Targeting the leukemia cell metabolism by the CPT1a inhibition
acetate is the primary product of hepatic mitochondrial beta-oxidation in Sus scrofa and that regulation during early development is mediated primarily via kinetic modulation of CPT I (show CPT1B Antibodies)
This study evaluated the effects of nonesterified fatty acids and glucose on carnitine palmitoyltransferase-I (CPT-I) mRNA expression in cultured bovine hepatocytes using real-time reverse transcription polymerase chain reaction and ELISA methods.
It was conclude that suppression of CPT (show DHDDS Antibodies) activity by positive energy balance appears to be specific for the liver in mid-lactating dairy cows.
beneficial effects of muscle CPT1mt expression suggest that a direct modulation of the malonyl-CoA/CPT1 partnership in skeletal muscle could represent a potential strategy to prevent obesity-induced insulin (show INS Antibodies) resistance
The data suggest that AMPK (show PRKAA1 Antibodies) is not required for the regulation of the intermediate filament interaction with CPT-I during exercise.
these results demonstrated that L-carnitine ameliorated liver inflammation and serum pro-inflammatory markers in cancer cachexia through regulating CPT I-dependent PPARg (show PPARG Antibodies) signaling
-Carnitine exerts its ameliorative effects in cancer cachexia in association with the PPAR-gamma (show PPARG Antibodies) signaling pathway.
Data show that peroxisome-proliferator-activated receptor beta (show PPARD Antibodies)/delta (PPARbeta (show PPARD Antibodies)/delta) activation restored the lipid-induced endothelial dysfunction by up-regulation of carnitine palmitoyltransferase)-1 (CPT-1).
Our results indicated that exercise-induced CPT1b (show CPT1B Antibodies) expression was at least in part mediated by HDAC5 (show HDAC5 Antibodies)/MEF2A (show MEF2A Antibodies) interaction.
an environment-dependent structural switch underlies the regulation of carnitine palmitoyltransferase 1A
miR (show MLXIP Antibodies)-370 acting via miR (show MLXIP Antibodies)-122 may have a causative role in the accumulation of hepatic triglycerides by modulating initially the expression of SREBP-1c (show SREBF1 Antibodies), DGAT2 (show DGAT2 Antibodies), and Cpt1alpha.
Results show that CREB (show CREB1 Antibodies) and HNF4alpha (show HNF4A Antibodies) bind the CPT (show DHDDS Antibodies) promoter, that PGC-1 (show PPARGC1A Antibodies) is involved in liver carnitine palmitoyltransferase I (CPT (show DHDDS Antibodies)) gene activation by cylic AMP (show TMPRSS5 Antibodies), and that PGC-1 (show PPARGC1A Antibodies) acts to coordinate the process of metabolic adaptation in the liver.
The mitochondrial oxidation of long-chain fatty acids is initiated by the sequential action of carnitine palmitoyltransferase I (which is located in the outer membrane and is detergent-labile) and carnitine palmitoyltransferase II (which is located in the inner membrane and is detergent-stable), together with a carnitine-acylcarnitine translocase. CPT I is the key enzyme in the carnitine-dependent transport across the mitochondrial inner membrane and its deficiency results in a decreased rate of fatty acid beta-oxidation. Alternatively spliced transcript variants encoding different isoforms have been found for this gene.
carnitine palmitoyltransferase 1A (liver)
, carnitine O-palmitoyltransferase 1, liver isoform-like
, CPT I
, carnitine O-palmitoyltransferase 1, liver isoform
, carnitine O-palmitoyltransferase I, liver isoform
, carnitine palmitoyltransferase I, liver
, carnitine palmitoyl transferase I liver isoform
, liver type carnitine palmitoyltransferase I
, mitochondrial carnitine palmitoyltransferase 1A
, carnitine palmitoyltransferase 1A
, carnitine palmitoyltransferase I
, carnitine palmitoyl transferase I isoform
, L-CPT I
, carnitine palmitoyltransferase 1, liver
, Carnitine palmitoyltransferase 1 alpha, liver isoform